AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are pleased to enclose herewith certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2022 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed notice published in newspapers regarding e-voting information for the 43rd Annual General Meeting of the Company in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the following newspapers on 7th July 2022: 1. Mumbai edition of Economic Times; 2. Mumbai edition of Navshakti. Please take in on your record. AJANTA PHARMA LTD. - 532331 - Reg. 34 (1) Annual Report.
We hereby inform that the Forty-Third Annual General Meeting ('AGM') of the Company will be held on Thursday, 4th August 2022 at 11.00 a.m. through Video Conferencing or Other Audio-Visual Means. Pursuant to Regulation 34(1) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report and Business Responsibility & Sustainability Report of the Company for the financial year 2021-22 along with Notice of the AGM. The Annual report, Business Responsibility & Sustainability Report and the Notice of AGM are being sent to the members through electronic mode and the same are also uploaded on the Company''s website http://www.ajantapharma.com/AnnualReports.aspx. Kindly take the same on your records. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed notice published in newspapers in terms of Circular No. 20/2020 dated 5th May 2020 issued by Ministry of Corporate Affairs, inter-alia, intimating that 43rd Annual General Meeting of the Company will be held on 4th August 2022 through Video Conferencing/Other Audio-Visual Means, in the following newspapers on 2nd July 2022: 1. Mumbai edition of Economic Times; 2. Mumbai edition of Navshakti. Please take in on your record. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 01, 2022 for Ravi P Agrawal, trustee Ravi Agrawal Trust AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and 'Ajanta's Code of Conduct for Insiders', the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of 30th June 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended 30th June 2022. Kindly take the above information on your record. AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information on loss of shares AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 27, 2022 for Aayush Agrawal, trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Allotment
The Company has allotted 4,27,08,385 Bonus Equity Shares of Rs. 2/- each as fully-paid up Bonus Equity Shares, in the proportion of 1:2, to the eligible Members whose names appeared on the register of Members/list of beneficial owners as on 23rd June 2022, i.e. record date fixed for this purpose. Consequently, the paid-up Equity Share Capital of the Company stands increased from Rs. 17,08,33,540 divided into 8,54,16,770 Equity Shares of Rs. 2/- each to Rs. 25,62,50,310 divided into 12,81,25,155 Equity Shares of Rs. 2/- each. As part of the aforesaid allotment 14,758 Bonus Equity Shares representing fractional entitlement(s) of eligible Members have been consolidated and allotted to a separate account opened for this purpose. Such equity shares would be sold at the prevailing market rate as soon as possible and the net sale proceeds after adjusting the cost and expenses in respect thereof, would be distributed amongst the members as per their respective fractional entitlements. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 23, 2022 for Aayush Agrawal, trustee Aayush Agrawal Trust